Reunion Neuroscience Inc T.REUN

Healthcare Biotechnology

Reunion Neuroscience Inc. is engaged in the psychedelic drug development company that provides therapeutic solutions for mental health conditions by developing serotonin receptor agonist compounds. The Company is developing the advancement of synthetic molecules targeting serotonin 5HT2A receptors. The Company’s products include RE104 and RE200. The Company’s lead asset, RE-104, which is a psychedelic drug being developed for post-partum and treatment resistant depression as a potential fast-acting antidepressant with durable efficacy. The RE104 as a potentially fast-acting treatment for the key indications of postpartum and treatment resistant depression. The Company is developing the RE200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psych activity for potential use in more chronic treatment paradigms and indications. The Company is focused on the research and development of its RE200 molecule group.

TSX:REUN - Post by User

Reunion Neuroscience Inc

<< Previous

Bullboard Posts

Next >>

(433)
•••

Comment by ark88on Jun 01, 2023 3:36pm

47 Views

Post# 35475550

RE:Cash offer.

Especially considering the deal stipulates the company must have $8mil minimum cash at closing. So they're pricing the company at $5.1 mil which equates to $0.43 per share offer.

<< Previous

Bullboard Posts

Next >>

Sego Resources announces $500K raise for Miner Mountain project